<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clinics (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Clinics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1807-5932</issn>
      <issn pub-type="epub">1980-5322</issn>
      <publisher>
        <publisher-name>Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22473415</article-id>
      <article-id pub-id-type="pmc">3297043</article-id>
      <article-id pub-id-type="doi">10.6061/clinics/2012(03)17</article-id>
      <article-id pub-id-type="publisher-id">cln_67p297</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Poststernotomy aspergillosis: successful treatment with voriconazole, surgical debridement and vacuum-assisted closure therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Siciliano</surname>
            <given-names>Rinaldo Focaccia</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cln_67p297">I</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Waisberg</surname>
            <given-names>Daniel Reis</given-names>
          </name>
          <xref ref-type="aff" rid="af2-cln_67p297">II</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Samano</surname>
            <given-names>Marcos Naoyuki</given-names>
          </name>
          <xref ref-type="aff" rid="af2-cln_67p297">II</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leite</surname>
            <given-names>Paulo Ferreira</given-names>
          </name>
          <xref ref-type="aff" rid="af3-cln_67p297">III</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>J&#xFA;nior</surname>
            <given-names>Paulo Tuma</given-names>
          </name>
          <xref ref-type="aff" rid="af4-cln_67p297">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barreiro</surname>
            <given-names>Guilherme Cardinali</given-names>
          </name>
          <xref ref-type="aff" rid="af4-cln_67p297">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strabelli</surname>
            <given-names>Tania Mara Varej&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cln_67p297">I</xref>
        </contrib>
        <aff id="af1-cln_67p297"><label>I</label>Hospital das Cl&#xED;nicas (HCFMUSP), da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Infection Control Team, Heart Institute (InCor), S&#xE3;o Paulo/SP, Brazil. </aff>
        <aff id="af2-cln_67p297"><label>II</label>Hospital das Cl&#xED;nicas (HCFMUSP), da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Division of Thoracic Surgery, Heart Institute (InCor), S&#xE3;o Paulo, Brazil. </aff>
        <aff id="af3-cln_67p297"><label>III</label>Hospital das Cl&#xED;nicas (HCFMUSP), da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Chronic Coronary Diseases Unit, Heart Institute (InCor), S&#xE3;o Paulo, Brazil. </aff>
        <aff id="af4-cln_67p297"><label>IV</label>Hospital das Cl&#xED;nicas (HCFMUSP), da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Division of Plastic Surgery, S&#xE3;o Paulo, Brazil. </aff>
      </contrib-group>
      <author-notes>
        <fn fn-type="con">
          <p>Siciliano RF, Waisberg DR, Samano MN, Leite PF, Tuma J&#xFA;nior P and Barreiro GC contributed to data collection and manuscript preparation. Strabelli TM performed critical revision of the manuscript.</p>
        </fn>
        <corresp id="c1-cln_67p297">E-mail: <email>rinaldo_focaccia@uol.com.br</email> Tel.: <phone>55 11 9891-6293</phone></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2012</year>
      </pub-date>
      <volume>67</volume>
      <issue>3</issue>
      <fpage>297</fpage>
      <lpage>299</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2012 Hospital das Cl&#xED;nicas da FMUSP</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <counts>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p><italic>Aspergillus</italic> spp. are ubiquitous in the environment, including the air, soil and decomposing material (<xref ref-type="bibr" rid="b1-cln_67p297">1</xref>). Human invasive aspergillosis arises from the inhalation and contiguous spread of <italic>Aspergillus</italic> to adjacent sites (e.g., petrous bone, the sinuses, the palate). Occasionally, human invasive aspergillosis can be the result of the direct extension or hematogenous spread from pulmonary foci or of intravenous drug abuse (<xref ref-type="bibr" rid="b1-cln_67p297">1</xref>). Invasive aspergillosis typically occurs in immunocompromised patients. Interestingly, some cases of surgical wound infection have been reported in immunocompetent individuals (<xref ref-type="bibr" rid="b1-cln_67p297">1</xref>). The occurrence of post-operative aspergillosis can be associated with the dissemination of spores in the operating room through the ventilation system, which can lead to the contamination of exposed tissue, the surgical materials, the prosthesis or the wound dressing (<xref ref-type="bibr" rid="b1-cln_67p297">1</xref>).</p>
      <p>Deep bone wound infection is a severe complication of coronary artery bypass graft (CABG) surgery. Chronic osteomyelitis is unusual, reported in 1 to 4% of patients, and is most frequently caused by staphylococci (<xref ref-type="bibr" rid="b2-cln_67p297">2</xref>,<xref ref-type="bibr" rid="b3-cln_67p297">3</xref>). <italic>Aspergillus</italic> spp. are rare but recently recognized causes of nosocomial chronic sternal infections, including especially difficult-to-treat cases of osteomyelitis/costochondritis of the sternum (<xref ref-type="bibr" rid="b1-cln_67p297">1</xref>).</p>
      <p>The optimal treatment for invasive bone aspergillosis is a combination of surgical treatment and appropriate antifungal therapy. Currently, voriconazole is being advocated for the treatment of invasive aspergillosis (<xref ref-type="bibr" rid="b4-cln_67p297">4</xref>,<xref ref-type="bibr" rid="b5-cln_67p297">5</xref>). Herein, we report an unusual and very interesting case of chronic osteomyelitis and costochondritis caused by aspergillosis of the chest wall following cardiac surgery in an immunocompetent patient who was successfully treated with vacuum-assisted closure therapy following surgical debridement and voriconazole therapy.</p>
    </sec>
    <sec>
      <title>CASE DESCRIPTION</title>
      <p>A 59-year-old man with diabetes, hypertension, and hypercholesterolemia who had undergone coronary angioplasty three and a half years earlier underwent CABG in September 2008. The postoperative course was uneventful, and the patient was discharged nine days after the bypass surgery. The patient had been well until February 2009, when progressive and intense chest pain around the sternal wound and shoulders developed, followed by malaise and weight loss (approximately 7 kg). One week before admission, the patient experienced purulent discharge at the sternal wound. On evaluation, he appeared tired and restless; his blood pressure was 120 &#xD7; 70 mmHg, his pulse was 100 beats per minute, his temperature was 36.9&#xB0;C, and his respiratory rate was 18 breaths per minute. There was hyperemia limited to the sternal wound; the remainder of the examination was normal. Laboratory results at the time of admission revealed a robust increase in plasma C-reactive protein (181 mg/dL); hemoglobin 9.7 mg/dl; leukocytes 10800/mm<sup>3</sup> (neutrophils 73%, lymphocytes 19%); platelets 633.000/mm<sup>3</sup>; urea 40 mg/dL; and creatinine 0.82 mg/dL. A chest tomography scan showed no bone abnormalities<bold>.</bold> All aerobic and anaerobic blood cultures (three samples) were sterile, and empiric intravenous therapy with vancomycin (1000 mg 12/12 hours) plus ciprofloxacin (400 mg 12/12 hours) was started<bold>.</bold> After four days, purulent wound discharge was observed. Technetium-99 m/Gallium-67 scintillography confirmed osteomyelitis in the region of the sternal wound.</p>
      <p>The patient underwent aggressive surgical debridement by thoracic and plastic surgeons with the removal of steel stitches, which revealed bilateral infection in the 3<sup>rd</sup> to 8<sup>th</sup> costal cartilages (<xref ref-type="fig" rid="f1-cln_67p297">Figure 1A</xref>), which were partially removed (<xref ref-type="fig" rid="f1-cln_67p297">Figure 1B</xref>), and vacuum-assisted closure (VAC) was used. The subject remained on VAC until new surgical debridement was performed bilaterally on the 6<sup>th</sup> ribs four days later (<xref ref-type="fig" rid="f1-cln_67p297">Figure 1C</xref>). The VAC device was removed, a Portovac&#xAE; tube was inserted, and the wound was closed primarily (<xref ref-type="fig" rid="f1-cln_67p297">Figure 1D</xref>). The patient had a favorable clinical evolution, without signs of systemic disseminated infection. Cartilaginous-bone tissue biopsies from the first and second surgical procedures showed <italic>Aspergillus</italic> osteomyelitis. The culture from the surgically removed sternal bone demonstrated the presence of <italic>Aspergillus</italic> spp. Treatment with a combination of vancomycin and ciprofloxacin was discontinued, and intravenous voriconazole (4 mg/kg per dose twice daily) was started six days after the first surgery. The Portovac&#xAE; tube was removed three days later, and the patient was discharged on the 18<sup>th</sup> day after the first surgical procedure. Intravenous voriconazole therapy was continued for a total of 42 days, when it was changed to oral capsules for 4 more months. After 3 months of voriconazole therapy, plasma C-reactive protein normalized, and Technetium-99 m/Gallium-67 scintillography showed no evidence of osteomyelitis. The patient currently remains very well, and the sternal wounds have healed completely.</p>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>Invasive aspergillosis affecting bone tissue is considered an unusual event, accounting for 1.8% to 5.6% of invasive aspergillosis cases (<xref ref-type="bibr" rid="b4-cln_67p297">4</xref>,<xref ref-type="bibr" rid="b6-cln_67p297">6</xref>), and has a high mortality rate (22.2% to 25%) (<xref ref-type="bibr" rid="b7-cln_67p297">7</xref>,<xref ref-type="bibr" rid="b8-cln_67p297">8</xref>). Vandecasteele et al. (<xref ref-type="bibr" rid="b7-cln_67p297">7</xref>) reported that sternal wound infections developed at a median of 14 days after cardiac surgery in nine patients during an outbreak of <italic>A. flavus</italic>. In contrast, our patient had an incubation period of at least two months and experienced an insidious course with chest pain and weight loss diagnosed as osteomyelitis four months after the symptoms first appeared. The lack of fever, wound inflammation, and purulent or serous wound discharge delayed the suspicion of surgical-site infection. Similarly long incubation times were reported by Verghese et al. (<xref ref-type="bibr" rid="b9-cln_67p297">9</xref>) (3 months) and Elahi et al. (2 months) in <italic>Aspergillus</italic> spp. osteomyelitis case reports (<xref ref-type="bibr" rid="b10-cln_67p297">10</xref>).</p>
      <p>Liposomal amphotericin B was considered the most suitable clinical treatment for invasive aspergillosis until recently (<xref ref-type="bibr" rid="b11-cln_67p297">11</xref>). Another potential option is the new formulation of oral itraconazole solution, which penetrates bone tissue more effectively and can be used as a prolonged outpatient treatment. Vandecasteele et al. reported a 77.7% overall cure rate when combining itraconazole and surgical debridement, although 42.8% of the patients had multiple relapses that required multiple treatment courses (<xref ref-type="bibr" rid="b7-cln_67p297">7</xref>). In the last few years, voriconazole emerged as the first-line antifungal agent for the treatment of invasive aspergillosis, based on its activity against <italic>Aspergillus,</italic> its acceptable side-effect profile, and the bioavailability of the oral formulation (<xref ref-type="bibr" rid="b12-cln_67p297">12</xref>). The adverse effects reported include transient visual disturbances, hepatotoxicity, and severe photosensitivity rash (<xref ref-type="bibr" rid="b12-cln_67p297">12</xref>), which must be taken into consideration when long courses of therapy are required, as in the case of osteomyelitis. Most studies have reported mild to moderate adverse effects, which did not lead to the discontinuation of therapy (<xref ref-type="bibr" rid="b4-cln_67p297">4</xref>,<xref ref-type="bibr" rid="b8-cln_67p297">8</xref>). In a case series of 12 patients with <italic>Aspergillus</italic> spp. osteomyelitis (<xref ref-type="bibr" rid="b8-cln_67p297">8</xref>), 63.6% responded to antifungal combinations including voriconazole. Mouas et al. (<xref ref-type="bibr" rid="b4-cln_67p297">4</xref>) reviewed the cases of 20 patients with bone aspergillosis treated with voriconazole (in 2 cases as first-line therapy and in 18 cases as salvage therapy because treatment had failed or the patient did not tolerate the previous antifungal therapy) and found that there was a satisfactory response in 55% of patients. In this study, when considering only immunocompetent patients, the response to therapy increased to 83.3% (5/6). The optimal duration of treatment for <italic>Aspergillus</italic> osteomyelitis is not known; however, a duration of several months is typically recommended (<xref ref-type="bibr" rid="b8-cln_67p297">8</xref>,<xref ref-type="bibr" rid="b10-cln_67p297">10</xref>).</p>
      <p>The treatment for invasive bone aspergillosis is based on the combination of surgical and medical approaches. Regardless of the antifungal drug used, most studies acknowledge the importance of surgical treatment. Stratov et al's review (<xref ref-type="bibr" rid="b5-cln_67p297">5</xref>) indicates that the rate of successful cure among patients treated with amphotericin B was higher when treatment was used in combination with surgery (75% <italic>versus</italic> 14%). Aggressive surgical debridement may be required, as shown in the current and previous reports (<xref ref-type="bibr" rid="b10-cln_67p297">10</xref>). In Elahi et al's case (<xref ref-type="bibr" rid="b10-cln_67p297">10</xref>), a similar patient underwent four debridements, which briefly consisted of partial resection of the sternum and the 6<sup>th</sup>, 7<sup>th</sup>, 8<sup>th</sup>, 9<sup>th</sup>, and 10<sup>th</sup> ribs; reinforcement of the bilateral pectoralis major flaps with omentum; and the creation of a lateral myocutaneous flap and a triangular skin flap in combination with use of the vacuum-assisted curative system for wound closure. In our case, the collaboration of thoracic and plastic surgeons was required to assure that well-vascularized defect coverage could be achieved through reconstruction. The retention of small foci of osteomyelitis and costochondritis may be considered the main reasons for the failure of surgical debridement given the extreme vulnerability of costal cartilage to infection, especially when denuded of perichondrium or devascularized due to the use of the internal mammary artery (<xref ref-type="bibr" rid="b10-cln_67p297">10</xref>). </p>
      <p>The use of vacuum-assisted closure therapy has dramatically changed the treatment of complex wounds (<xref ref-type="bibr" rid="b13-cln_67p297">13</xref>). Regarding chest wounds, most algorithms recommend its use following surgical debridement, as it allows for wound drainage, granulation stimulation, increased tissue blood flow, chest wall stabilization, chest cavity isolation to prevent contamination, and the maintenance of a moist environment (<xref ref-type="bibr" rid="b13-cln_67p297">13</xref>). Consequently, the rate of reinfection and the length of the patient's hospital stay are decreased (<xref ref-type="bibr" rid="b14-cln_67p297">14</xref>). Soft-tissue flaps are usually used for the definitive closure of deep sternal wounds, after vacuum-assisted closure therapy has been employed for several days (<xref ref-type="bibr" rid="b14-cln_67p297">14</xref>). In our case, however, it was possible to perform primary closure.</p>
      <p>In conclusion, invasive bone aspergillosis should be considered when dealing with slowly progressive chest wall wound infections following cardiac surgery, even in immunocompetent patients. It is increasingly accepted that voriconazole may be the drug of choice for the treatment of <italic>Aspergillus</italic> osteomyelitis, and aggressive surgical debridement is recommended to improve the rate of treatment success.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>No potential conflict of interest was reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1-cln_67p297">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pasqualotto</surname><given-names>A</given-names></name><name><surname>Denning</surname><given-names>D</given-names></name></person-group><article-title>Post-operative aspergillosis</article-title><source>Clin Microbiol Infect</source><year>2006</year><volume>12</volume><fpage>1060</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">17002605</pub-id></element-citation>
      </ref>
      <ref id="b2-cln_67p297">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zacharias</surname><given-names>A</given-names></name><name><surname>Habib</surname><given-names>RH</given-names></name></person-group><article-title>Factors predisposing to median sternotomy complications. Deep vs superficial infection</article-title><source>Chest</source><year>1996</year><volume>110</volume><fpage>1173</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8915216</pub-id></element-citation>
      </ref>
      <ref id="b3-cln_67p297">
        <label>3</label>
        <element-citation publication-type="journal">
<collab>Parisian Mediastinitis Study Group</collab><article-title>Risk factor for deep sternal wound infection after sternotomy: a prospective, multicenter study</article-title><source>J Thorac Cardiovasc Surg</source><year>1996</year><volume>111</volume><fpage>1200</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8642821</pub-id></element-citation>
      </ref>
      <ref id="b4-cln_67p297">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mouas</surname><given-names>H</given-names></name><name><surname>Lutsar</surname><given-names>I</given-names></name><name><surname>Dupont</surname><given-names>B</given-names></name><name><surname>Fain</surname><given-names>O</given-names></name><name><surname>Herbrecht</surname><given-names>R</given-names></name><name><surname>Lescure</surname><given-names>F</given-names></name><etal/></person-group><article-title>Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases</article-title><source>Clin Infect Dis</source><year>2005</year><volume>40</volume><fpage>1141</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15791514</pub-id></element-citation>
      </ref>
      <ref id="b5-cln_67p297">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stratov</surname><given-names>I</given-names></name><name><surname>Korman</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>P</given-names></name></person-group><article-title>Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2003</year><volume>22</volume><fpage>277</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12734721</pub-id></element-citation>
      </ref>
      <ref id="b6-cln_67p297">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Denning</surname><given-names>D</given-names></name><name><surname>Stevens</surname><given-names>D</given-names></name></person-group><article-title>Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases</article-title><source>Rev Infect Dis</source><year>1990</year><volume>12</volume><fpage>1147</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">2267490</pub-id></element-citation>
      </ref>
      <ref id="b7-cln_67p297">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vandecasteele</surname><given-names>S</given-names></name><name><surname>Boelaert</surname><given-names>J</given-names></name><name><surname>Verrelst</surname><given-names>P</given-names></name><name><surname>Graulus</surname><given-names>E</given-names></name><name><surname>Gordts</surname><given-names>B</given-names></name></person-group><article-title>Diagnosis and treatment of Aspergillus flavus sternal wound infections after cardiac surgery</article-title><source>Clin Infect Dis</source><year>2002</year><volume>35</volume><fpage>887</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12228828</pub-id></element-citation>
      </ref>
      <ref id="b8-cln_67p297">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horn</surname><given-names>D</given-names></name><name><surname>Sae-Tia</surname><given-names>S</given-names></name><name><surname>Neofytos</surname><given-names>D</given-names></name></person-group><article-title>Aspergillus osteomyelitis: review of 12 cases identified by the Prospective Antifungal Therapy Alliance registry</article-title><source>Diagn Microbiol Infect Dis</source><year>2009</year><volume>63</volume><fpage>384</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">19249181</pub-id></element-citation>
      </ref>
      <ref id="b9-cln_67p297">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verghese</surname><given-names>S</given-names></name><name><surname>Chellamma</surname><given-names>T</given-names></name><name><surname>Cherian</surname><given-names>K</given-names></name></person-group><article-title>Osteomyelitis of the rib caused by Aspergillus flavus following cardiac surgery</article-title><source>Mycoses</source><year>2009</year><volume>52</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">18522699</pub-id></element-citation>
      </ref>
      <ref id="b10-cln_67p297">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elahi</surname><given-names>M</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Spears</surname><given-names>J</given-names></name><name><surname>McClurken</surname><given-names>J</given-names></name></person-group><article-title>Recalcitrant chest wall Aspergillus fumigatus osteomyelitis after coronary artery bypass grafting: successful radical surgical and medical management</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>79</volume><fpage>1057</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">15734444</pub-id></element-citation>
      </ref>
      <ref id="b11-cln_67p297">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevens</surname><given-names>D</given-names></name><name><surname>Kan</surname><given-names>V</given-names></name><name><surname>Judson</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>V</given-names></name><name><surname>Dummer</surname><given-names>S</given-names></name><name><surname>Denning</surname><given-names>D</given-names></name><etal/></person-group><article-title>Practice guidelines for diseases caused by Aspergillus</article-title><source>Infectious Diseases Society of America. Clin Infect Dis</source><year>2000</year><volume>30</volume><fpage>696</fpage><lpage>709</lpage></element-citation>
      </ref>
      <ref id="b12-cln_67p297">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walsh</surname><given-names>T</given-names></name><name><surname>Anaissie</surname><given-names>E</given-names></name><name><surname>Denning</surname><given-names>D</given-names></name><name><surname>Herbrecht</surname><given-names>R</given-names></name><name><surname>Kontoyiannis</surname><given-names>D</given-names></name><name><surname>Marr</surname><given-names>K</given-names></name><etal/></person-group><article-title>Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><fpage>327</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18177225</pub-id></element-citation>
      </ref>
      <ref id="b13-cln_67p297">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orgill</surname><given-names>DP</given-names></name><name><surname>Bayer</surname><given-names>LR</given-names></name></person-group><article-title>Update on Negative-Pressure Wound Therapy</article-title><source>Plast Reconstr Surg</source><year>2011</year><volume>127</volume><fpage>105S</fpage><lpage>115S</lpage><pub-id pub-id-type="pmid">21200280</pub-id></element-citation>
      </ref>
      <ref id="b14-cln_67p297">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cowan</surname><given-names>KN</given-names></name><name><surname>Teague</surname><given-names>L</given-names></name><name><surname>Sue</surname><given-names>SC</given-names></name><name><surname>Mahoney</surname><given-names>JL</given-names></name></person-group><article-title>Vacuum-assisted wound closure of deep sternal infections in high-risk patients after cardiac surgery</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>80</volume><fpage>2205</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16305872</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-cln_67p297" position="float">
      <label>Figure 1</label>
      <caption>
        <p>A) Bilateral infection in the 3<sup>rd</sup> to 8<sup>th</sup> costal cartilages and ribs. <bold>B</bold>) 3<sup>rd</sup> to 8<sup>th</sup> bilateral costal cartilage removal. <bold>C</bold>) Second bilateral debridement of the 6<sup>th</sup> ribs on the 4<sup>th</sup> post-operative day. <bold>D</bold>) Final apperance of the wound with insertion of a Portovac&#xAE; tube.</p>
      </caption>
      <graphic xlink:href="cln-67-03-297-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
